1hyo: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
Line 1: Line 1:
[[Image:1hyo.jpg|left|200px]]
{{Seed}}
[[Image:1hyo.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1hyo|  PDB=1hyo  |  SCENE=  }}  
{{STRUCTURE_1hyo|  PDB=1hyo  |  SCENE=  }}  


'''CRYSTAL STRUCTURE OF FUMARYLACETOACETATE HYDROLASE COMPLEXED WITH 4-(HYDROXYMETHYLPHOSPHINOYL)-3-OXO-BUTANOIC ACID'''
===CRYSTAL STRUCTURE OF FUMARYLACETOACETATE HYDROLASE COMPLEXED WITH 4-(HYDROXYMETHYLPHOSPHINOYL)-3-OXO-BUTANOIC ACID===




==Overview==
<!--
Fumarylacetoacetate hydrolase (FAH) catalyzes the hydrolytic cleavage of a carbon-carbon bond in fumarylacetoacetate to yield fumarate and acetoacetate as the final step of Phe and Tyr degradation. This unusual reaction is an essential human metabolic function, with loss of FAH activity causing the fatal metabolic disease hereditary tyrosinemia type I (HT1). An enzymatic mechanism involving a catalytic metal ion, a Glu/His catalytic dyad, and a charged oxyanion hole was previously proposed based on recently determined FAH crystal structures. Here we report the development and characterization of an FAH inhibitor, 4-(hydroxymethylphosphinoyl)-3-oxo-butanoic acid (HMPOBA), that competes with the physiological substrate with a K(i) of 85 microM. The crystal structure of FAH complexed with HMPOBA refined at 1.3-A resolution reveals the molecular basis for the competitive inhibition, supports the proposed formation of a tetrahedral alkoxy transition state intermediate during the FAH catalyzed reaction, and reveals a Mg(2+) bound in the enzyme's active site. The analysis of FAH structures corresponding to different catalytic states reveals significant active site side-chain motions that may also be related to catalytic function. Thus, these results advance the understanding of an essential catabolic reaction associated with a fatal metabolic disease and provide insight into the structure-based development of FAH inhibitors.
The line below this paragraph, {{ABSTRACT_PUBMED_11154690}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 11154690 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_11154690}}


==About this Structure==
==About this Structure==
Line 30: Line 34:
[[Category: Witte, J F.]]
[[Category: Witte, J F.]]
[[Category: Beta-sandwich roll]]
[[Category: Beta-sandwich roll]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Fri May 2 19:22:09 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 1 10:09:00 2008''

Revision as of 07:09, 1 July 2008

File:1hyo.png

Template:STRUCTURE 1hyo

CRYSTAL STRUCTURE OF FUMARYLACETOACETATE HYDROLASE COMPLEXED WITH 4-(HYDROXYMETHYLPHOSPHINOYL)-3-OXO-BUTANOIC ACID

Template:ABSTRACT PUBMED 11154690

About this Structure

1HYO is a Single protein structure of sequence from Mus musculus. Full crystallographic information is available from OCA.

Reference

Mechanistic inferences from the crystal structure of fumarylacetoacetate hydrolase with a bound phosphorus-based inhibitor., Bateman RL, Bhanumoorthy P, Witte JF, McClard RW, Grompe M, Timm DE, J Biol Chem. 2001 May 4;276(18):15284-91. Epub 2001 Jan 11. PMID:11154690

Page seeded by OCA on Tue Jul 1 10:09:00 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=1hyo&oldid=609383"